First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

Summary

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.

Timeline

Start

2026-07-13

Primary completion

2029-07-07

Completion

2029-09-17

Drugs

Indications